Abstract
Rotavirus is the leading cause of severe diarrhea among children under five worldwide, especially in low- and middle-income countries (LMICs). Although vaccination is the best strategy for preventing rotavirus infection, obstacles leading to poor vaccine effectiveness undermine its impact in LMICs. This study aimed to evaluate the impact and cost-effectiveness of the current two-dose Rotarix vaccine schedule in Malawi compared to two alternative vaccine delivery schedules and a next-generation neonatal vaccine (RV3-BB) from 2025-2034. The cost-effectiveness of rotavirus vaccine strategies in Malawi was evaluated from both the government and societal perspectives using estimates of moderate-to-severe and non-severe rotavirus cases derived from a mathematical model of rotavirus transmission dynamics and published estimates of health-seeking behaviors and costs as inputs. A probabilistic sensitivity analysis was performed to evaluate the robustness of our results to parameter uncertainty. Over a ten-year time horizon, the current two-dose strategy was predicted to avert over 1.5 million cases and 90,000 disability-adjusted life-years (DALYs) and cost $104.87 per DALY averted compared to no vaccination from the government perspective. Adding a third dose at 14 weeks could avert about 1 million more cases and cost $5 million more than the current strategy. The neonatal RV3-BB vaccine could avert 1.1 million cases and 41,000 DALYs due to rotavirus and save about $3.7 million compared to the current strategy. The current rotavirus vaccine program in Malawi is cost-effective and saves lives compared to no vaccination. However, adding a third dose is likely to be cost-effective at a willingness to pay (WTP) of $138.38 per DALY averted, while switching to the neonatal RV3-BB vaccine when available is likely to be cost-effective at a WTP above $45.89 per DALY averted.
Competing Interest Statement
DH is currently receiving grant support from Seqirus UK Ltd for the evaluation of influenza vaccines and grant support and personal consultancy fees from Merck & Co (Kenilworth, New Jersey, USA) for rotavirus strain surveillance; DH has received honoraria for presentation at a Merck Sharp & Dohme (UK) Limited symposium on vaccines; DH has previously received research-initiated and industry-initiated research grant support from GlaxoSmithKline Biologicals for evaluation of rotavirus vaccination in the UK and from GSK, Sanofi Pasteur, and Merck & Co for rotavirus strain surveillance. KCJ has received research grant support from GlaxoSmithKline Biologicals for work on rotavirus vaccines. All other authors declare no competing interests.
Funding Statement
This work was supported by funding from the US National Institutes of Health/National Institute of Allergy and Infectious Diseases (R01AI112970 to VEP), the Wellcome Trust (Programme grant number: 091909/Z/10/Z), the Bill and Melinda Gates Foundation (OPP1180423 and INV-046917), and US Centres for Disease Control and Prevention funds through the World Health Organization (2018/815189-0), and the UK National Institute for Health and Care Research (NIHR) Global Health Research Group on Gastrointestinal Infections at the University of Liverpool using UK aid from the UK Government to support global health research (NIHR133066). Nigel Cunliffe is a NIHR Senior Investigator (NIHR203756). Daniel Hungerford was funded through a NIHR Post-doctoral Fellowship (PDF-2018-11-ST2-006). Nigel Cunliffe, Khuzwayo C Jere and Daniel Hungerford are also affiliated with the NIHR Health Protection Research Unit in Gastrointestinal Infections at the University of Liverpool, a partnership with the UK Health Security Agency in collaboration with the University of Warwick. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the NIHR, the Department of Health and Social Care, the UK government or the UK Health Security Agency.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript or is available online at https://github.com/CatherineWenger/RotavirusCEA-Malawi.git.
